The new drug development in MBC focuses on human clinical trials. The core mission of Division of New Drug Development is to conduct phase I to IV clinical trials, of which product d......
more

  Molecular diagnostics is the leading growing segment within the in vitro diagnostics (IVD) market. The anticipated annual growth rate of molecular diagnostics segment is 15.3%, with ......
more

1. 2008-03-17
2. Oncolys BioPharma Ties Up with Medigen Biotech. For Telomelysin

1. 2008-03-05
2. Oncolys BioPharma and Medigen Biotechnology Enter Strategic Alliance and Licensing Agreement

1. 2007-11-28
2. [Announcment] MBC Collaborates with Academia Sinica for Liver Cancer Development

1. 2007-10-17
2. MBC Co-ops with NTU for New Drug Development

1. 2007-09-03
2. Tetralogy of Complementary Double-Core Business Model

1. 2007-08-06
2. MBC Enters Blood Screening Market in China

1. 2007-07-09
2. Taiwanese Bid for Anti-Cancer Drug

1. 2007-07-02
2. Big Pharmas Favor BioMed-Industry in Taiwan

1. 2007-06-16
2. New Drug PI-88 Decreases Liver Cancer Recurrence to 34%

1. 2007-06-15
2. Liver Cancer Treatment Breakthrough by PI-88 Phase II Trial

1. 2007-04-24
2. New Drug PI-88 Prevents Liver Cancer Recurrence

1. 2007-01-17
2. MBC to Profit from PI-88 Ahead of Time